ABSTRACT

To choose the most relevant ten papers constitutes a challenge in several ways. We have elaborated this selection based on the papers we find to be most useful and ground-breaking for the clinician faced daily by the infectious problems in onco-hematological patients. The selection has been structured in four parts: bacterial infections, viral infections, fungal infections and infections related with new drugs in onco-hematological patients.

Key Words: bacterial infections, letermovir, aspergillosis.

INTRODUCTION

During the last two years, a significative number of papers have been published on the field of infection in onco-hematological patients. To choose the most relevant ten papers constitutes a challenge in several ways. On one hand, the subjectivity of the author is unavoidable; an apparently less relevant article may, to the eyes the author, contribute with more fresh and useful ideas than one published in one of the top journals. Furthermore, on the other hand, there may be a relevant article that we forget to highlight.

Therefore, we have elaborated this selection based on the papers we find to be most useful and ground-breaking for the clinician faced daily by the infectious problems in onco-hematological patients. I apologize in advance if you do not find a paper you considered to be better or more relevant than the mentioned in the following selection.

This selection has been structured in four parts. First, we will comment the most innovative papers on bacterial infection and especially on the crucial topic of the development of antibiotic resistance in the onco-hematological patients. In a second part we will review an article on viral infection. In the third part we will review what is new in fungal infection, mainly on new risk populations and the raise in Pneumocistis jirovecii infections in onco-hematological patients. Finally, we will comment papers referring to new drugs for the management of onco-hematological diseases and how may they relate to the risk of infection. After each of the four sections, we will sum up the most relevant messages.

BACTERIAL INFECTIONS

The increasing number of infections caused by multi-drug resistant bacteria (MDRB) constitutes a major problem. This fact is of especial relevance in onco-hematological patients.
Given their disease and the treatments received, these patients often present significant immunosuppression. This leads to numerous infections, thus requiring frequent and prolonged antibiotic exposure. A better knowledge on epidemiology of these infections and the development and implementation of measures to reduce antibiotic resistance are crucial.

In the first study, signed by Averbuch et al [1] al all Gram-negative rod resistant (GNR) bacteremias occurring during 6 months post-HSCT (2/14–5/15) were prospectively collected and analyzed for rates and risk factors for resistance to fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), carbapenems, and multidrug resistance. Fifty-five centres from 25 countries (mostly from Europe) participated in the study, reporting data on 655 GNR episodes and 704 pathogens in 591 patients (Enterobacteriaceae, 73%; nonfermentative rods, 24%; and 3% others). Half of GNRs were fluoroquinolone and noncarbapenem resistant; 18.5% carbapenem resistant; 35.2% multidrug resistant. e total resistance rates were higher in allo- geneic HSCT (allo-HSCT) vs. autologous HSCT (auto-HSCT) patients (P < .001) but similar in community-acquired infections. Noncarbapenem resistance and multidrug resistance were higher in auto-HSCT patients in centers providing vs. not providing fluoroquinolone prophylaxis and emphasized the necessity of multivariable analysis revealed resistance risk factors in allo-HSCT patients: fluoroquinolone resistance: adult, prolonged neutropenia, breakthrough on fluoroquinolones; noncarbapenem resistance: hospital-acquired infection, breakthrough on noncarbapenems or other antibiotics (excluding fluoroquinolones, noncarbapenems, carbapenems), donor type; carbapenem resistance: breakthrough on carbapenem, longer hospitalization, intensive care unit, previous other antibiotic therapy; multidrug resistance: longer hospitalization, breakthrough on β-lactam/β-lactamase inhibitors, and carbapenems. Inappropriate empiric therapy and mortality were significantly more common in infections caused by resistant bacteria. In summary, the study questions the recommendation of fluoroquinolone prophylaxis and emphasizes the necessity of empiric antibiotic protocols based on the knowledge of resistance rates of each centre.

Gudiol et al [2], signed the second study where β-lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum- β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs, if active in vitro, might be carbapenem- sparing alternatives for the treatment of BSI due to ESBLs in in high-risk hematological patients. This strategy may prove useful in limiting the spread of carbapenem resistance in this high-risk population.

The last study lead by Aguilar-Guisado et al [3], also from Spain, proposes a useful approach to reduce unnecessary exposure to antimicrobials and demonstrates that in high-risk patients with haematological malignancies and febrile neutropenia, empirical antibiotic therapy (EAT) can be discontinued after 72 h of apyrexia and clinical recovery irrespective of their neutrophil count. In four years, 157 episodes among 709 patients assessed for eligibility were randomized (78 to stop EAT after 72 h or more of apyrexia plus clinical recovery and 79 to the control group- when neutropenia was recovered). The mean number of EAT-free days was significantly higher in the experimental group than in the control group. One patient died in the experimental group (from hepatic veno-occlusive disease after an allogeneic haemopoietic stem-cell transplantation) and three died in the control group (one from multigraft failure, one from invasive pulmonary aspergillosis, and one from a post-chemotherapy intestinal perforation).

**VIRAL INFECTIONS**

Cytomegalovirus (CMV) infection is a leading cause of illness and death in patients who have undergone allogeneic hematopoietic-cell transplantation. Over the past 20 years, clinicians have adopted a preemptive strategy. Thus, the development of safe and effective antiviral agents for CMV prophylaxis remains a major goal in transplantation.

Letermovir is an antiviral agent that inhibits CMV replication by binding to components of the terminase complex (UL51, UL56, or both), at a dose of 240 mg per day was highly effective in preventing CMV viremia after engraftment in a study published in 2014 [4]. Three years later, a phase 3, randomized, double-blind, placebo-controlled, superiority trial [5], resulted in a significantly lower risk of clinically significant CMV infection than placebo (122 of 325 patients [37.5%] vs. 103 of 170 [60.6%], P<0.001). The frequency and severity of adverse events were similar in the two groups. All-cause mortality at week 48 after transplantation was 20.9% among letermovir recipients and 25.5% among placebo recipients.

So, letermovir is a safe and effective drug for preventing CMV infection when used through day 100 after transplantation.

**FUNGAL INFECTIONS**

With the use of prophylaxis in high-risk hematological patients, the incidence of invasive aspergillosis (IA) has reduced in this group to below 3% [6]. On the other hand, with the use of new targeted or immunomodulatory drugs in the management of hematological malignancies an increase of IA is observed in patients considered of medium-low risk for fungal infection. We chose two articles, both of them from Livio Pagan’s group focusing on the epidemiological changes based on the host.

In the first of them [7] is a unicentric, retrospective study that demonstrates that the new treatment strategies in lymphoproliferative disorders, including immunomodulating and...
immunosuppressive agents, in addition to cytotoxic treatments and a more frequent application of autologous HSCT have caused an increased risk of IFIs among these patients. In this study, it seems particularly evident in MM and aggressive NHL patients, particularly when after HSCT. These changes in the epidemiology induced to modify the diagnostic workup for IFIs, now more frequent than in the past, in these patients. Although the incidence of IFI is below 5%, it is quite higher than the observed in these same patients 10 years before. Prospective studies are required to evaluate the potential usefulness of prophylaxis in these patient groups.

In the second study [8], the same group analyzed the current data regarding the epidemiology of and risk factors for IFIs in patients with HMs. The concept *non-static level of risk* for IFI is an interesting contribution. For instance, the risk of IFI could be low in patients at the time of diagnosis of the underlying hematological malignancy, while in the following months, the same patient could be considered at high risk in the case of *non-responsiveness* to the anti-neoplastic treatment. This review might offer a useful tool for designing future studies with the aim of optimizing the diagnostic procedures and therapeutic strategies for preventing and treating IFIs in patients with hematological malignancies.

*Pneumocystis jiroveci* (PJ) pneumonia is often diagnosed in onco-hematological patients undergoing chemotherapy or targeted therapies, frequently in combination with systemic steroids, that even in doses as low as the equivalent of 20 mg of prednisone a day for 4 weeks constitute and important risk factor [9]. In addition, PJ pneumonia in these patients presents distinctive features including higher mortality that may be aggravated by a later diagnosis and delayed treatment. On the other hand, indications for prophylaxis in oncological patients are not well established. ECLL guidelines have published three papers regarding epidemiology [10], treatment [11] and prophylaxis [12] of PJ pneumonia in hematological patients.

The following publications have provided more new data on this condition:

Takemoto et al [13], knowing that PJ can colonize in the lower airway and the air vesicles of some healthy individuals, analyzed the presence of PJ DNA with a nested PCR technique in bronchoalveolar lavage samples among outpatients during cancer chemotherapies and compared it with healthy controls. PJ DNA was detectable in 46% of specimens from cancer patients undergoing chemotherapy, and it was not significantly different among types of cancer and chemotherapy regimens. Detection of PJ DNA was lower among healthy non-smokers (20%) and high among healthy smokers (47%). They conclude that quit smoking and antibiotic prophylaxis may be necessary for cancer patients during chemotherapy.

In another study [14], as much as 27% of HIV-negative patients with PJ pneumonia presented with more than 200 μL CD4+ lymphocytes, thus questioning this threshold for prophylaxis frequently used in HIV-positive patients.

As a personal opinion, due to the lack of solid clinical data, prophylaxis should be considered in patients receiving immunosuppressive treatment or chemotherapy, prolonged treatment of steroid and/or present persistent lymphopenia.

**NEW TREATMENTS FOR THE MANAGEMENT OF ONCO-HEMATOLOGICAL DISEASES AND ITS IMPACT IN INFECTION**

It is difficult to establish the risk of infection associated with a specific directed therapy due to the high number of confounders. In the first place, the onco-hematological condition itself is often associated with a higher number of infections, sometimes caused by opportunist pathogens. In the second place, treatments previously received by the patient may have a persistent effect on the immunitory system, even long after its interruption. Additionally, treatments administered for counteracting the adverse effects of these drugs, such as steroids, may further influence the risk of infection. Finally, a high number of patients receiving the treatment for a long time would be necessary, in conjunction with a significant number of infectious events, to establish an exact quantification of the risk.

An excellent review about risk of infectious complications in hemato-oncological patients treated with kinase inhibitors has been published by Reinwald et al [15] and is summarized in table 1. Recent publications have also focused its attention on ibrutinib and the increase in the incidence of fungal infections. Chamilos et al [16] presented opportunistic infections caused by *P. jirovecii* and *Cryptococcus neoformans*, ubiquitous airborne fungi in patients undergoing ibrutinib, with hematological cancers historically considered at low risk for IFI. The spectrum and severity of IFI observed in these patients implies the presence of a complex immunodeficiency that may not be solely attributed to mere inhibition of Bruton tyrosine kinase. When aspergillosis occurred, it was more frequently observed within the first 4 months of treatment and affected more frequently in patients with central nervous system disease (primary central nervous system lymphoma), also receiving steroids (71%) and with refractory or relapsed malignancies (100% of cases).

The risk of infection among patients receiving immune checkpoint blockade is unknown. After reviewing medical records of 740 patients with melanoma who received immune checkpoint blockers, del Castillo et al [17] concluded that serious infection occurred in 54 patients (7.3%). The main risk factors were treatment with corticosteroids and/or infliximab to handle complications associated with immune related adverse events. Future studies will need to address the best approach to prevent infectious complications in these patients; cotrimoxazole prophylaxis is recommended when steroids are initiated. Aspergillosis and CMV enterocolitis need also to be in consideration when adverse events are treated with immunosuppressors.

A French group [18] reviewed 2 cases of tuberculosis reported to French database of adverse events related with biological drugs in onco-hematological patients and 3 more pub-
lized. Although tuberculosis seems to be rare (1/1000 patients
in France), its reactivation may be favored by the specific ac-
tion of anti PD-1 agents. All patients should probably be tested
with an IGRA before the initiation of anti PD-1 treatment, and
closer collaboration between infectious disease specialists and
oncologists is advisable.

We are at the beginning of a new period in medical his-
tory. New drugs are being added to the onco-hematological
armamentarium every day, and most of them have an immu-
nomodulatory effect. We must learn its negative effects on the
defense against infections and how to manage them, we have
to think about the infections in new populations of risk, and
most important of all, we have to keep working in multidisci-
plinary teams for the benefit of our patients.

REFERENCES

1. Averbuch D, Tridello G, Hoek J, Mikulsa M, Akan H, Yan ez San Se-
gundo L. et al. Antimicrobial Resistance in Gram-Negative Rods
Causing Bacteremia in Hematopoietic Stem Cell Transplant Recip-
ients: Intercontinental Prospective Study of the Infectious Diseas-
es Working Party of the European Bone Marrow Transplantation
Group. Clin Infect Dis. 2017;65(11):1819–1828. doi: 10.1093/cid/cix646.
PMID: 29020364

2. Gudiel C, Royo-Cebreos C, Abdala E, Akova M, Álvarez R, Maestro-de la
Calle G, Cano A et al. BICAR Study Group. Efficacy of β-Lactam/β-Lacta-
maseme Inhibitor Combinations for the Treatment of Bloodstream Infection
Due to Extended-Spectrum-β-Lactamase-Producing Enterobacte-
riaceae in Hematological Patients with Neutropenia. Antimicrob Agents
Chemother. 2017;61(8). doi: 10.1128/AAC.00164-17.

3. Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Ceb-
breos C, Falantes J, et al. Optimization of empirical antimicrobial
therapy in patients with haematological malignancies and febrile
neutropenia (How Long study): an open-label, randomised, con-
trolled phase 4 trial. Lancet Haematol. 2017;4(12):e573-e583. doi:
10.1016/S2352-3026(17)30211-9.

4. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M,
Groth C et al; AIC246 Study Team. Letemovi r for cytomegalovirus
prophylaxis in hematopoietic-cell transplantation. N Engl J Med.
2014;370(19):1781–9. doi: 10.1056/NEJMoa1309533.

5. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte
RF et al. Letemovi r Prophylaxis for Cytomegalovirus in Hematopa-
ioetic-Cell Transplantation. N Engl J Med. 2017;377(25):2433-
2444. doi: 10.1056/NEJMoa1706640.

6. Duarte RF, Sánchez-Ortega I, Cuesta I, Arnáiz M, Patiño B, Fernán-
dez de Sevilla A et al. Serum galactomannan-based early detection
of invasive aspergillosis in hematology patients receiving effective
antimold prophylaxis. Clin Infect Dis. 2014;59(12):1696-702. doi:
10.1093/cid/ciu673

7. Tisi MC, Hohaus S, Cuccaro A, Innocenti I, De Carolis E, ZA T et
al. Invasive fungal infections in chronic lymphoproliferative
disorders: a monocentric retrospective study. Haematologica.
2017;102(3):e108-e111. doi: 10.3324/haematol.2016.151837.

8. Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Facci R et
al; SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine nelle
Emopatie Maligne) Group; Other Authors:. Risk stratification for
invasive fungal infections in patients with hematological malig-
nancies: SEIFEM recommendations. Blood Rev. 2017;31(2):17-29.
doi: 10.1016/S2352-3026(17)30157-7.

9. Calero-Bernal ML, Martín-Garrido I, Donazar-Ezcurra M, Limp-
er AH, Carmona EM. Intermittent Courses of Corticosteroids Also
Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients.
Can Respir J. 2016;2016:2464791. PMID: 27721666

---

### Table 1

| Pathway target inhibitor | Drugs | Indicative infections related to drug | Possible prophylaxis recommended |
|--------------------------|-------|-------------------------------------|---------------------------------|
| BCR-ABL | Imatinib, Dasatinib, Nilotinib, ponatinib, Bosutinib | HSV, CMV and Hepatitis reactivation, Neutropenic fever | May be considered |
| BCR-Pathway-inhibitory | Ibrutinib, Idelalisib | Pneumonia | May be considered |
| mTOR | Temsirolimus, Everolimus | VZV and HSV reactivation, Invasive Aspergillosis | Aciclovir and Cotrimoxazole must be considered |
| JAK | Ruxolitinib, Tofactinib | None specific | None |
| EGFR-ALK | Erlotinib, Gefitinib, Afatinib, Crizotinib, Ceritinib | Upper Respiratory tract Infections | None |
| Multikinase (esp VEGF) | Sorafenib, Sunitinib, Regorafenib, Axitinib, Pazopanib | VZV and HSV reactivation, Invasive Aspergillosis | Pneumocystis jiroveci Pneumonia |
| BRAF/MEK | Vemurafenib, Dabrafenib, Trametinib | None specific | None |
10. Cordonnier C, Alanio A, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, et al; Fifth European Conference on Infections in Leukemia (ECIL-5); a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors’ response. J Antimicrob Chemother. 2017;72(4):1266–1268. doi: 10.1093/jac/dkw580.

11. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P; 6th European Conference on Infections in Leukemia (ECIL-6), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organisation for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71(9):2405–13. doi: 10.1093/jac/dkw158.

12. Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al; 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–404. doi: 10.1093/jac/dkw157.

13. Takemoto S, Ebara M, Hasebe S, Yakushijin Y. A study on the colonization of Pneumocystis jirovecii among outpatients during cancer chemotherapy and among healthy smokers. J Infect Chemother. 2017;23(11):752–756. doi: 10.1016/j.jiac.2017.07.003.

14. Messiaen PE, Cuyp S, Dejagere T, van der Hilst JC. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review. Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12651.

15. Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomark Insights. 2016;10(Suppl 3):55–68. doi: 10.4137/BMI.S22430.

16. Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clin Infect Dis. 2018;66(1):140–148. doi: 10.1093/cid/cix687.

17. Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clin Infect Dis. 2016;63(11):1490–1493. PMID:27501841

18. Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect. 2018;24(3):216–218. doi:10.1016/j.cmi.2017.12.003.